[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Nottingham\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":710},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,66,0,25,[9,47,75,99,127,155,195,225,246,271,295,325,345,369,399,425,453,488,513,536,568,613,637,660,687],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652888","mri-parameters-as-biomarkers-in-cystic-fibrosis-fempto-100652888",false,"NCT07780344","MRI Parameters as Biomarkers in Cystic Fibrosis (FEMPTO)","A Feasibility Study Evaluating MRI Parameters as Biomarkers of the Effect of a Secretagogue in Cystic Fibrosis (FEMPTO)","FEMPTO","Inclusion Criteria:\n\n* • Participant is willing and able to give informed consent for participation in the study.\n\n  * Proven diagnosis of CF.\n  * Aged between 18-60 years.\n  * Ability to conform to the study protocol, including overnight fasting, dietary and lifestyle restriction, administering linaclotide and placebo intervention, MRI scanning, consuming the two study meals and blue muffins, and rating stool frequency and appearance.\n\nExclusion Criteria:\n\n* Pregnant (current or planned during the study duration) or breastfeeding\n* Currently taking regular medicines (i.e., pain relief medication like ibuprofen\u002Fparacetamol) apart from cystic fibrosis medicines (i.e., pancreatic enzyme replacement therapy (PERT) medication, CFTR modulators). There are some other medicines it is OK to take such as:\n* Some antidepressants (SSRIs or low-dose tricyclics)\n* Antihistamines (for allergies)\n* The contraceptive pill\n* Any resections (surgery) of the intestines, not including removal of the appendix\n* Serious medical conditions including any other digestive disorder unrelated to CF.\n* Taken a course of intravenous or oral antibiotics in the last 2 weeks (except prophylactic antibiotics such as azithromycin).\n* Inability to stop opiates\n* Inability to have MRI scans (this could be due to some metallic implants, pacemaker, history of metallic foreign body in your eye and penetrating eye injury)\n* Night shift work during the week before study days\n* BMI under 18.5 or above 35 kg\u002Fm2.\n* Taken part in a CTIMP study in the last 4 weeks involving invasive procedures.\n* currently has chronic diarrhoea symptoms.","ALL","18 Years","50 Years",{"count":22,"type":23},12,"ESTIMATED","INTERVENTIONAL",[26],"NA","Cystic fibrosis (CF) is an inherited condition that affects several organs, including the gut. People with CF often experience uncomfortable digestive symptoms such as bloating, gas, abdominal pain, and constipation. The root cause is that the gut produces thicker-than-normal mucus, which slows things down and makes it harder for the bowel to work properly.\n\nCurrent treatments such as laxatives, enemas, or surgery can be inconvenient and don't always work well. There is a real need for better options, and for a clearer understanding of how the CF gut behaves and responds to treatment.\n\nThis study will use MRI, a non-invasive imaging technique, to look at how fluid moves through the gut in adults with CF and the impact of linaclotide. Linaclotide is a licensed medication used to treat chronic constipation and irritable bowel syndrome. It works by encouraging the gut to release more fluid, helping things move more easily. It acts locally in the gut and is not absorbed into the bloodstream. Early research suggests it may help in CF in a way that does not rely on correcting the underlying genetic fault, making it a promising avenue to explore.\n\nParticipants will include people with different bowel habits, including those who tend towards constipation and those who tend towards diarrhoea. The scans will help researchers check whether certain MRI measurements can reliably detect changes in gut fluid and movement.\n\nThis is a feasibility study; its main objective is to test whether these MRI measurements are useful and practical, and support a sample size calculation, in future CF studies investigating linaclotide effects.",[29],"Cystic Fibrosis (CF)",[31,32,33],"MRI","cystic fibrosis","linaclotide","NOT_YET_RECRUITING","2026-08-18",{"date":37,"type":38},"2026-08-21","ACTUAL",{"date":40,"type":23},"2026-09",{"date":42,"type":23},"2027-08",{"name":44,"class":45},"University of Nottingham","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100644519","closed-loop-tes-non-invasive-stimulation-100644519","NCT07671079","Closed-loop tES-non-invasive Stimulation","Closed-loop Non-invasive Stimulation for Improving Brain and Mental Health in Healthy Individuals","CLIBM","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study\n* Aged between 18 and 40\n* Good general health\n* Not consume alcohol 48 hours prior study visit\n* Not currently taking any medications (except contraceptive pills) or if on long-term medication for a non-neurological\u002Fnon-psychiatric condition (r.g. inhalers) to be considered otherwise healthy and stable with no symptoms\n* Be right handedness\n\nExclusion Criteria:\n\n* Inability to complete MRI\u002FFUS\u002FTMS\u002FtES safety questionnaire and \u002F or informed consent process.\n* Current or previous diagnosis of a neurological, neurosurgical, psychiatric disorders.\n* Other significant medical condition (specific details to be reviewed by the CI prior to inclusion).\n* Currently pregnant, breast feeding, or on planned pregnancy.\n* Medication intake (such as beta-blocker, glucocorticoids, anti-depressants, anti-inflammatory drugs in the last 7d).\n* Medication intake (such as antidepressants, antipsychotics, anti-epileptics, beta blockers, glucocorticoids, anti-inflammatories, benzodiazepines, hypnotics, sedating antihistamines or any illicit substances in the past seven days).\n* Significant use of medication or recreational drugs that affect the nervous system.\n* Excessive consumption of alcohol.\n* Known allergy to any required consumables (such as aquasonic gel).\n* History of anaphylaxis to any substance\n* Have tightly coiled, curly or voluminous texture hair type (e.g., hair type 3, 4, or afro hair).\n* Having skin disease or sensitive skin on or close to the head.",true,"40 Years",{"count":58,"type":23},30,[26],"The goal of this study is to establish if non-invasive closed-loop neuromodulation is an effective approach to enhance cognitive function in healthy 18-40 years old volunteers. The main questions it aims to answer are:\n\n* Can closed-loop stimulation increase stimulation effectiveness?\n* Can closed-loop focused ultrasound specifically engage with excitatory or inhibitory neural populations in the target structure as measured through MRS?\n* Can observed stimulation outcomes for FUS be predicted through connectome analysis and computational models of indirect changes?\n\nResearchers will compare different closed-loop options to their open-loop counterpart to see if closed-loop approaches can increase efficacy and reduce the variability of the stimulation compared to open-loop approaches.\n\nParticipants will:\n\n* Answer some questionnaires at the start of the study and after each intervention session.\n* Undertake a MRI scanning session.\n* Undertake one open-loop FUS session.\n* Undertake one tES session.\n* Undertake one closed-loop FUS sessions involving tES and FUS, followed by a MRI scanning\n* Undertake one sham FUS session\n* Attend one visit in person to assess eligibility through questionnaires and one cognitive task",[62],"Closed-loop Brain Stimulation",[64,65,66,67],"neuromodulation","electrical stimulation","transcranial low-intensity focused ultrasound stimulation","closed-loop neuromodulation","2026-08-15",{"date":70,"type":38},"2026-08-19",{"date":40,"type":23},{"date":73,"type":23},"2027-12",{"name":44,"class":45},{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100617031","exploring-resistance-exercise-training-plus-high-intensity-interval-training-rehiit-as-cancer-prehabilitation-100617031","NCT07313332","Exploring Resistance Exercise Training Plus High-Intensity Interval Training (ReHIIT) as Cancer Prehabilitation","Exploring Resistance Exercise Training Plus High-Intensity Interval Training (ReHIIT) as Cancer Prehabilitation: A Healthy Control Group Pilot Study","ReHIIT_CON","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Availability and willingness to attend the Royal Derby Hospital site for a minimum of 8 exercise sessions and 2 assessment sessions across the study period.\n\nExclusion Criteria:\n\n* BMI \\\u003C18 or \\>35 kg\u002Fm2\n* Known active cance\n* Known metabolic disease\n* Current known neurological or musculoskeletal conditions (e.g. epilepsy)\n* Active known cardiovascular, cerebrovascular or respiratory disease - e.g:\n* Uncontrolled hypertension (systolic BP \\> 160 mmHg or diastolic BP \\>100 mmhg)\n* Myocardial infarction within the last 6 months or unstable angina\n* Heart failure (New York Heart association Class III\u002FIV)\n* Arrhythmia\n* Right to left cardiac shunt\n* Aneurysm of a named blood vessel\n* COPD\n* Pulmonary hypertension\n* Exercise-induced or brittle asthma\n* Previous stroke\u002Ftransient ischaemic attack\n* Abnormal ECG results (at the discrepancy of the study doctor)\n* Patients who are unable to undergo CPET based on ATS\u002FACSS guidelines \\^\n* Pre-existing clotting disorder known to the participant or anticoagulant use\n* Family history of severe bleeding requiring medical intervention\n* Participation in a research study in the last 3 months involving invasive procedures or an inconvenience allowance (ALL UoN FMHS UREC approved studies)\n* Pregnant or breastfeeding",{"count":84,"type":23},14,[26],"Colorectal cancer is the fourth most common cancer in the UK. Prehabilitation, including exercise, can improve recovery from surgery. This pilot study investigates the combined effects of resistance and high-intensity interval training (ReHIIT) in healthy adults to establish baseline physiology and responses for comparison with cancer patients",[88,89],"Healthy Adult Male and Female Volunteers","Intervention","RECRUITING","2026-08-12",{"date":93,"type":38},"2026-08-14",{"date":95,"type":38},"2026-01-01",{"date":97,"type":23},"2027-12-01",{"name":44,"class":45},{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":24,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100651299","lived-experience-narratives-in-dementia-100651299","NCT07757178","Lived Experience Narratives in Dementia","Improving the Quality of Life for People Living With Dementia and Carers: The Design and Development of a Dementia Specific Online Narrative-Based Intervention With a Feasibility Study","LEND","General Inclusion Criteria (apply across WP1-WP3)\n\n* Adults aged 18+.\n* Able to give informed consent and participate meaningfully in the required tasks.\n* Adequate communication ability in the required study language\n\nGeneral Exclusion Criteria (apply across WP1-3)\n\n* Living in a hospital or healthcare institution at the time of the study.\n* Refusal or inability to provide informed consent, or lack of capacity to consent.\n* Inability to comprehend participant information or communicate meaningfully","99 Years",{"count":109,"type":23},60,[26],"The Lived Experience Narratives in Dementia (LEND) research programme involves five work packages (WP). WP1 explores how people living with dementia use narratives and how narratives can impact them. Findings will support the development of LEND theory. WP 2-3 focus on developing the digital Online LEND Intervention, assessing its usability and acceptability, and conducting a feasibility study within NHS memory assessment and community services. Activities across the first three WPs include interviews, focus groups, user-testing sessions, engagement evaluation interviews, and a two-arm randomised feasibility trial using a range of outcome measures. Findings from this stage will inform refinement of the intervention and determine the feasibility of progressing to a future randomised controlled trial (RCT) of the Online LEND Intervention. WP4 is the Online LEND Intervention two-arm RCT. WP5 involves dissemination. The protocol for WP4 and 5 have not yet been developed and rely on results from WP1-3.",[113,114,115,116,117],"Dementia","Neuro-Degenerative Disease","Alzheimer Disease","Caregiver Burden","Caregiver Burnout","2026-08-05",{"date":120,"type":38},"2026-08-11",{"date":122,"type":38},"2025-11-17",{"date":124,"type":23},"2029-07",{"name":44,"class":45},2,{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":24,"phases":136,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":46},"100650778","early-virtual-ankle-rehabilitation-evar-acceptability-100650778","NCT07751107","Early Virtual Ankle Rehabilitation (EVAR): Acceptability","Early Virtual Ankle Rehabilitation (EVAR): A Proof-of-concept Feasibility Study Exploring Patient Acceptability Using Qualitative Interviews With Nested Quantitative Analysis.","EVAR-Accept","Eligibility Criteria:\n\nAdults who have undergone ankle fracture surgery\n\nInclusion Criteria:\n\n* Adults of either sex, aged 18 years and older, with no upper limit.\n* Within the last 21 days, they underwent open reduction and internal fixation (ORIF) for an ankle fracture; AO44, AO43B and AO43C classifications and subclassifications.\n* Any orthopaedic weightbearing instructions, ranging from non-weightbearing to unrestricted weightbearing.\n\nExclusion Criteria:\n\n* Unable or unwilling to give informed written consent for any reason.\n* Unable or unwilling to engage with the early ankle rehabilitation programme.\n* Severe open fractures (Gustilo Anderson G3)\n* A clinical decision was made that the ankle should remain cast immobilised until the subsequent orthopaedic review, which is beyond 21 days post-surgery.\n* If, in the opinion of the clinical and research staff, it is in the patient's best interest to be excluded due to presentations such as, but not limited to:\n\n  * Soft tissue concerns where early movement may risk tissue breakdown.\n  * Comorbidities associated with slowed tissue healing, such as non-healing leg\u002Ffoot ulcers, medicating diabetics and a lack of protective distal sensation (e.g. peripheral neuropathy).\n  * There is a plausible concern that the individual has been or will be non-compliant with the most recent treatment advice, for example, weightbearing contrary to orthopaedic advice.\n* Inability to adhere to study procedures, including, but not limited to, the following:\n\n  * Lacking the capacity to adhere to the study intervention (minor assistance from family and friends is permissible).\n  * Unable to converse fluently in English for the interviews or lack the capacity or ability to complete the study questionnaire in English.\n  * Does not have access to and\u002For rudimentary capacity to use virtual clinic technology (assistance from family and friends is permissible).\n* Currently taking part or having taken part in a research study in the last 3 months that involves\u002Finvolved invasive procedures. Where the circumstances of a potential participant are ambiguous, clarification with the CI or PI should be sought.",{"count":58,"type":23},[26],"The goal of this study is to learn about people's experiences of how physiotherapy is received having recently had surgery for a broken ankle. The ways to receive the rehabilitation will be via video, call Early Virtual Ankle Rehabilitation (EVAR), and face-to-face at the hospital. The content of the rehabilitation programme will be the same for both groups.\n\nThe main questions that the study aims to answer are:\n\n* During the early weeks of recovery after ankle surgery, how happy are people to have physiotherapy support by video call (EVAR) compared with face-to-face appointments at the hospital?\n* Is it practical to run a larger study on how well EVAR helps recovery from ankle fracture surgery?\n\nParticipants will be put into one of two groups by chance:\n\n* A group that has EVAR, with physiotherapy appointments by video call to their home.\n* A group that has face-to-face physiotherapy appointments at the hospital.\n\nAll participants will receive the same early physiotherapy programme. The only difference between the groups is how physiotherapy support is received.\n\nParticipants in both groups will:\n\n* Start the physiotherapy programme at about 2-weeks after surgery.\n* Receive advice and information about recovery.\n* Carry out ankle exercises at home, while sitting or lying.\n* Have at least two physiotherapy appointments between 2 and 6 weeks after surgery.\n* At week-6, take part in an interview to explore the experiences of the physiotherapy programme and method of interacting with the physiotherapist.\n* Complete questionnaires about their recovery and their experiences, with a final set at about 12 weeks after surgery.\n\nBetween 21 to 30 adults who have had surgery for a broken ankle will take part in this study. About twice as many participants will have physiotherapy appointments by video call as those who have appointments at the hospital.\n\nThe information from this study will help researchers understand whether physiotherapy support by video call are a good fit for people recovering from ankle surgery. It will also help decide whether a larger study should be carried out in the future.",[139],"Ankle Fracture",[141,142,143,144,145,146],"Physical therapy","Physiotherapy","Exercise","Rehabilitation","Virtual","Remote","2026-08-03",{"date":149,"type":38},"2026-08-07",{"date":151,"type":23},"2026-07-22",{"date":153,"type":23},"2027-09-30",{"name":44,"class":45},{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":24,"phases":165,"briefSummary":166,"conditions":167,"keywords":178,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":194},"100600119","the-impact-of-pectin-supplementation-on-systematic-inflammation-pathway-gut-microbiome-and-metabolic-health-in-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-masld-100600119","NCT07093346","The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Randomised, Placebo-Controlled, Dietary Intervention Study","PEC-MASLD","Inclusion Criteria:\n\nInclusion criteria for the main study:\n\n* Patients with clinical diagnosis of MASLD (formerly termed non-alcoholic fatty liver disease (NAFLD)), having assessment suggesting that liver fat \\> 5% (e.g. histological evidence or\u002F and Transient Elastography using Controlled Attenuation Parameter (CAP)- FibroScan™ in the past month and\u002For liver imaging (such as ultrasound, computerized tomography (CT) or magnetic resonance imaging (MRI)).\n* Participants willing and able to give informed consent for participation in the study.\n* Participants aged ≥18 years who have a body mass index (BMI) between 18.5 and 39.9 kg\u002Fm2 and stable weight (weight gain or loss ≤ 3kg) for the past 3 months.\n* For diabetic participants: controlled blood glucose levels Haemoglobin A1C (HbA1c) \\\u003C7.0% (\\\u003C53 mmol\u002Fmol) \\[1\\].\n* Able to undergo CAP-FibroScan™.\n\nInclusion criteria for healthy participants who will have MRI scans:\n\n* Participants willing and able to give informed consent for participation in the study.\n* Participants aged ≥18 years.\n* participants with CAP\\\u003C250 kpa\\\u003C8kP by a FibroScan™ within the past 6 months.\n\nExclusion Criteria:\n\nExclusion criteria for the main study:\n\n* Have allergy toward soya, milk or chocolate.\n* Have allergy toward pectin.\n* Participants on vegan diet.\n* Have eating disorders or difficulties or gastrointestinal conditions e.g. malabsorptive conditions such as coeliac, Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD) or gastroparesis.\n* Have chronic malnutrition condition.\n* History of major surgery which potentially limits participation or completion of the study.\n* History of previous intestinal surgery known to affect food intake or digestive function, including bariatric surgery.\n* Use of antibiotics, antifungal medications, probiotics or prebiotics 90 days before the start of the study.\n* Are taking the following medications: immunosuppressants, amiodarone and\u002For perhexiline.\n* Are currently following or anticipated to commence a specialised commercially available weight loss diet and\u002For program or concomitant use of any weight loss medication or herbal weight loss products.\n* History of side effects towards probiotics or prebiotics.\n* History or current psychiatric illness.\n* History or current neurological condition (e.g. epilepsy).\n* Participants with other liver abnormalities.\n* Evidence of monogenic metabolism diseases such as Lysosomal acid lipase deficiency (LALD), Wilson disease, Hypobetalipoproteinemia, or inborn errors of metabolism.\n* Have had a weight change exceeding 3 kg within 3 months.\n* Uncontrolled diabetes, active malignancy, or chronic infections.\n* Having symptoms of active infection.\n* Excessive alcohol intake defined as self-reported intakes greater than 21 units per week in men, and 14 units per week in women.\n* Participants who are pregnant, breast feeding or actively planning pregnancy will be excluded from the study.\n* Participation in any other trial in the last 3 months.\n\nExclusion criteria for healthy volunteers MRI scans and patients optional MRI scans:\n\n* Contraindications for MRI scanning: having pacemakers, defibrillators, neurostimulators, prohibited medical implants, and foreign bodies (e.g. bullets, shrapnel, metal slivers), history of metallic foreign body in eye(s) and penetrating eye injury that could present a risk during an MRI scan.\n* Difficulty breathing or inability to lie flat, as well as conditions that could worsen under stress (such as anxiety or panic disorders, claustrophobia, uncontrolled hypertension, or seizure disorders) severe enough to prevent undergoing an MRI.",{"count":164,"type":23},45,[26],"The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce systemic inflammation and improve gut microbiota composition in adults recently diagnosed with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The main question it aims to answer is:\n\n-How does dietary Low-methoxy (LM) pectin supplementation affect systematic inflammation pathways such as those mediated by gut microbiota composition and what are the impacts on general metabolic indicators in individuals with MASLD?\n\nResearchers will compare a group taking 15g of LM-pectin with 10g of cocoa powder to a placebo group receiving 10g of placebo with 10g of cocoa powder to see if LM-pectin has measurable effects on inflammation and gut microbiota.\n\nParticipants will:\n\n* Take a daily supplement for 6 weeks: either 15g of LM-pectin with 10g of cocoa powder (intervention), or 10g of placebo with 10g of cocoa powder (control)\n* Provide stool and fasting blood samples before and after the intervention\n* Undergo anthropometric measurements (weight, height, waist\u002Fhip ratio, and blood pressure)\n* Complete a case report form (CRF) including demographics and health\u002Fmedical history\n* Undergo a FibroScan™ to assess liver health\n* (Optional) Participate in MRI scans to evaluate gut permeability",[168,169,170,171,172,173,174,175,176,177],"Nonalcoholic Fatty Liver Disease","Nonalcoholic Fatty Liver Disease (NAFLD)","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","MASLD","NAFLD","Metabolic Dysfunction-Associated Steatotic Liver Disease","NAFLD (Nonalcoholic Fatty Liver Disease)","NAFLD (Non-alcoholic Fatty Liver Disease)","NAFLD - Non-Alcoholic Fatty Liver Disease","NAFLD - Nonalcoholic Fatty Liver Disease",[179,180,171,172,168,181,182,183,184,185,173],"LM pectin","pectin","Systemic Inflammatory Response","Dietary Fiber","Dietary Fibre","Diet","gut microbiota","2026-07-28",{"date":188,"type":38},"2026-07-29",{"date":190,"type":38},"2025-06-10",{"date":192,"type":23},"2027-03-31",{"name":44,"class":45},3,{"id":196,"slug":197,"hasResults":12,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":202,"minAge":4,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":46},"100591228","intra-operative-detection-of-positive-margins-and-lymph-nodes-in-breast-surgery-100591228","NCT06977698","Intra-operative Detection of Positive Margins and Lymph Nodes in Breast Surgery","Multimodal Spectroscopic Imagining for Intra-operative Assessment in Breast Cancer Surgery.","Inclusion criteria\n\n* Patients undergoing breast surgery wide local excision (WLE).\n* Able to give informed consent.\n* Any age.\n\nExclusion criteria\n\n• Patients where there is any doubt regarding the diagnosis from pathologist as ascertained by previous diagnostic biopsy.","FEMALE",{"count":204,"type":23},120,"OBSERVATIONAL","In this project, the investigators will develop novel optical coherence tomography (OCT)-Raman spectroscopy and autofluorescence (AF)-Raman spectroscopy systems based on a selective sampling approach optimised for high-resolution analysis of whole lumpectomy specimens and sentinel lymph node (SLN) biopsies, respectively. The aim of using optical coherence tomography is not to detect cancer directly, but rather to identify adipose tissue so that large adipose regions can be excluded from subsequent Raman spectroscopy measurements.\n\nAlthough OCT has limited ability to distinguish tumour tissue from the surrounding normal stroma, adipose tissue exhibits a distinctive appearance in optical coherence tomography images because of its low backscattering properties, resulting from adipocytes that are filled with lipids and contain small, flattened nuclei. In contrast, benign dense tissue (stroma, ducts, and lobules) and malignant tissue produce much stronger backscattering signals. These characteristic patterns enable adipose tissue to be distinguished from other breast tissues using classification models based on optical coherence tomography reflectivity profiles, achieving 94% sensitivity and 93% specificity. Excluding adipose tissue from further analysis reduces the number of Raman spectroscopy measurements required, allowing the remaining, smaller tissue regions to be examined to discriminate between benign and malignant tissue. This flexible and adaptable scanning strategy is expected to improve both diagnostic accuracy and scanning speed, enabling complete assessment of surgical margins within clinically practical timescales.\n\nIn addition, the investigators will develop a novel (AF)-Raman spectroscopy system based on a selective sampling approach optimised for high-resolution analysis of sentinel lymph node specimens. The purpose of incorporating autofluorescence imaging is to identify the optimal sampling locations for subsequent Raman spectroscopy measurements, thereby improving the efficiency of tissue interrogation while maintaining diagnostic accuracy.",[208],"Breast Cancer Invasive",[210,211,212,213,214,215,216,217],"Breast cancer","Margins","Breast conserving surgery","Raman Spectroscopy","Sentinel Lymph Node","computational pathology.","intra-operative imaging","Autofluorescence",{"date":219,"type":38},"2026-07-30",{"date":221,"type":38},"2023-10-01",{"date":223,"type":23},"2027-04-01",{"name":44,"class":45},{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":46},"100550402","drug-induced-liver-injury-itching-study-100550402","NCT06446609","Drug-induced Liver Injury: Itching Study","Understanding the Natural History and Impact of Itching (Pruritus) in Patients With Drug-induced Liver Injury (DILI)","Inclusion Criteria:\n\n* Age ≥18 (no upper age limit) and able to give informed written consent\n* Exposure to potential causal agent and diagnosed with suspected acute DILI defined as meeting one of the following analytical thresholds at enrolment (visit 1):\n\n  * alanine transaminase (ALT) ≥5 times upper limit of normal (ULN) or\n  * alkaline phosphatase ≥2 times ULN or\n  * ALT ≥3 times ULN plus total bilirubin \\>2 times ULN\n\nResults from clinical test samples collected within 36h of visit will be acceptable (as DILI is an acute event, patients are expected to recover or deteriorate quickly so enrolment aligned with diagnostic tests is necessary).\n\nExclusion Criteria:\n\n* Patients with comorbidities of eczema and urticaria associated with pruritus\n* Patients with existing diagnosis of blood-borne viral hepatitis infection (Hepatitis B\u002FC\u002FE)",{"count":233,"type":23},50,"Idiosyncratic drug-induced liver injury (DILI) is an unpredictable adverse hepatic reaction to a medication used in its therapeutic dose. DILI is the second most common cause of itching in adult Hepatology after biliary obstruction. In particular cholestatic or mixed pattern types of DILI (in which bile flow from the liver is impaired) are associated with long-lasting effects as well as reduced quality of life. There is therefore an urgent need to determine the incidence and natural history of itching in DILI and establish a network of centres that will form a basis for a clinical trial to investigate a novel intervention to treat these.",[236,237],"Drug Induced Liver Injury","Pruritus","2026-07-24",{"date":240,"type":38},"2026-07-27",{"date":242,"type":38},"2025-06-30",{"date":244,"type":23},"2028-05",{"name":44,"class":45},{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":46},"100632620","action-falls-for-domiciliary-care-100632620","NCT07516054","Action Falls for Domiciliary Care","Adapting and Implementing the Action Falls Programme for Domiciliary Care: A Focus on Rural and Coastal Communities","Inclusion Criteria:\n\nObservations:\n\n* Domiciliary care workers working in the settings and localities in the sample and providing support to older people\n* Social care practitioners working in the settings and localities in the sample\n\nInterviews:\n\n* Older people (65 years and over) supported by domiciliary care and providing support to older people\n* Relatives of older people supported by domiciliary care\n* Social care practitioners\n* Owners of domiciliary care\n* Commissioners and senior decision makers in Lincolnshire County Council and Nottinghamshire County Council\n\nCo-design workshops:\n\n* Domiciliary care workers working in BelleVie Care\n* Older people (65 years and over) supported by domiciliary care\n* Relatives of older people supported by domiciliary care\n* Social care practitioners\n* Owners of domiciliary care\n* Commissioners and senior decision makers in Lincolnshire County Council and Nottinghamshire County Council\n\nExclusion Criteria:\n\n* Lack of capacity to give informed consent",{"count":254,"type":23},65,"Action Falls is a programme that helps older adults avoid falls and injuries. It finds out why someone might fall and suggests ways to help, like checking their medication and encouraging them to stay active. It was created to try and prevent falls in care homes. It includes training for care home staff, a manual, and a checklist of what to look out for and what to do. Home care providers, local care groups, and older adults who live in the community think Action Falls could be useful too, to help reduce the number of falls in older adults who live at home. The investigators have identified that the programme could be particularly useful for older people who are supported by home care services.\n\nThe goal of this project is to develop ways to deliver and keep the programme running for older people supported by home care services. A future study will then try it out and see it helps people manage falls in home care.\n\nThe first part aims to plan and make changes to the current Action Falls programme to make sure it is suitable for use in home care settings. The investigators will do this by\n\n* observing what happens on home care visits\n* asking people who are supported by and who deliver home care how the programme needs to be changed.\n\nIn a future study the investigators will then deliver the programme across home care in Nottinghamshire and Lincolnshire and evaluate how well it has worked. The study will focus on coastal and rural areas.",[257],"Falls",[259,260,261,262,263],"falls","implementation","independence","social care","home care","2026-07-23",{"date":238,"type":38},{"date":267,"type":38},"2026-07-15",{"date":269,"type":23},"2028-06",{"name":44,"class":45},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":55,"sex":18,"minAge":279,"maxAge":280,"enrollmentInfo":281,"targetDuration":283,"studyType":205,"phases":4,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":4},"100647511","biomarkers-for-babies-and-young-children-with-ataxia-telangiectasia-100647511","NCT07709728","Biomarkers for Babies and Young Children With Ataxia Telangiectasia","Biomarkers for Babies and Young Children With Ataxia Telangiectasia (The BOBCAT Study)","BOBCAT","1. Participants with A-T\n\n   * Inclusion criteria\n\n     * Genetic diagnosis of Ataxia Telangiectasia\n     * Aged under two years old at the time of first recruitment\n     * Parents\u002F guardians able to give informed consent\n   * Exclusion criteria\n\n     * Contraindication to MRI\n     * Diagnosis of any other neurogenetic disease\n     * On approved treatment targeting neurodegeneration in A-T at the time of first recruitment\n     * Participating in the trial of novel therapy targeting neurodegeneration in A-T at the time of first recruitment\n\n   NB - co-recruitment to other observational studies or trials is permitted. If a family chooses to enrol their child in an interventional study targeting neurodegeneration, provided that the intervention trial allows co-recruitment, we would like to retain the participant in the BOBCAT study until its conclusion. In this circumstance, the child's data would not be considered as part of the natural history dataset but would instead be used to demonstrate the feasibility of collecting longitudinal quantitative imaging and other biomarker data in people with A-T during infancy and early childhood.\n2. Participants without A-T\n\n   * Inclusion criteria\n\n     * Child undergoing general anaesthesia at Nottingham University Hospitals NHS Trust for minor surgical procedures or diagnostic MRI.\n     * Aged 0-5 years (to match the age range of participants with A-T throughout the longitudinal study).\n     * Parents\u002F guardians able to give informed consent\n   * Exclusion criteria\n\n     * Diagnosis of any neurological or neurodevelopmental disease\n     * Diagnosis of any other significant chronic childhood illness\n     * On any long-term prescribed treatments","0 Years","5 Years",{"count":282,"type":23},56,"4 Years","The goal of this observational study is to identify progressive changes of quantitative brain and lung imaging, serum and movement-related biomarkers reflecting disease progression in pre-symptomatic infants and very young children (0-5 yo) with a genetic diagnosis of A-T, that could be used in future early-life intervention trials.",[286],"Ataxia Telangiectasia","2026-07-13",{"date":289,"type":38},"2026-07-16",{"date":291,"type":23},"2026-09-01",{"date":293,"type":23},"2029-08-31",{"name":44,"class":45},{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":18,"minAge":303,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":24,"phases":306,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":46},"100646509","phase-4-stopping-ppi-therapy-in-inactive-ibd-100646509","NCT07691138","Stopping PPI Therapy in Inactive IBD","STOpping PPI Therapy in Inactive IBD Study (STOP-IT): A Feasibility Study","STOP-IT","Inclusion Criteria:\n\n* Aged 16 years or older.\n* An IBD diagnosis as defined through SNOMED codes in primary care databases \\[Appendix 5\\]\n* Taking a PPI regularly for \\>6 months prior to enrolment\n* Patient-confirmed compliance with PPI therapy (\\>75% of prescribed doses)\n* Able to give full, independent valid Informed consent\n* Stable disease as defined by no change in medication or IBD-related surgery for the last 3 months.\n\nExclusion Criteria:\n\n* Unable to participate fully in all aspects of the clinical trial.\n* Barrett's oesophagus\n* Peptic disease at a recent upper GI endoscopy\n* Zollinger-Ellison Syndrome\n* Eosinophilic oesophagitis\n* Chronic NSAID usage\n* Pulmonary fibrosis.\n* Declined consent to data sharing\n* History of dementia\n* Terminal illness\n* Present malignancy\n* Active history of mental illness\n* In a care home\n* Alcohol misuse\n* Illicit drug misuse","16 Years",{"count":305,"type":23},80,[307],"PHASE4","To investigate the feasibility of proton pump inhibitor (PPI) withdrawal in inflammatory bowel disease (IBD); the data collected will provide valuable information to inform a future multi-centre randomised controlled trial.\n\nEvidence suggests that patients with IBD taking PPIs respond less well to medication and require hospital treatment more frequently than patients not taking PPIs. This may be due to changes in the gut microbiota associated with PPI use.\n\nA future definitive trial is planned to investigate clinical outcomes in patients who stop PPIs compared with those who continue PPIs, in order to determine the safety implications of PPI use in IBD. However, several uncertainties remain which require investigation before such a trial can be undertaken. It is currently unknown how many patients with IBD take PPIs, how many can successfully stop taking PPIs, how many would be willing to stop treatment, and how many would remain off treatment long term. In some cases, withdrawal of PPIs may result in a short-term increase in acid reflux symptoms. The willingness of patients to participate in such a study is also unknown. This study will be conducted in GP practices, a setting in which IBD trials have not previously been undertaken.\n\nThe study will recruit 80 participants with IBD aged 16 years and over who have been taking PPIs regularly for more than six months. Half of participants will be randomised to discontinue PPI therapy. Participants will be followed up for 12 months. The study will provide information regarding recruitment rates within GP practices, optimal methods for PPI withdrawal, and whether stopping PPIs affects IBD outcomes.",[310,311],"Ulcerative Colitis (UC)","Crohn's Disease",[313,314,311,315,316],"proton pumb inhibitor","PPI","Ulcerative Colitis","PPI Withdrawal","2026-07-06",{"date":319,"type":38},"2026-07-08",{"date":321,"type":23},"2026-07-01",{"date":323,"type":23},"2027-07-01",{"name":44,"class":45},{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":55,"sex":18,"minAge":303,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":46},"100589614","naza---nottinghamastra-zeneca-prospective-ibd-cohort-study-100589614","NCT06956703","NAZA - Nottingham\u002FAstra ZenecA Prospective IBD Cohort Study","NAZA","Inclusion Criteria:\n\n1\\. Provision of signed and dated, written informed consent before any study specific procedures\n\nAND\n\n2a. Patients of at least 16 years of age with active Crohn's disease defined as: CRP \\> = 5 mg\u002FL OR FCP \\> = 250 μg\u002Fg OR Visible ulcerations on ileocolonoscopy with a total SES-CD \\> = 7, or \\> = 4 if disease is confined to the terminal ileum OR visable active disease on cross-sectional imaging. Are switching to a new mechanism of action (MOA) onto anti-TNF therapy or ustekinumab or upadacitinib\n\nOR\n\n2b. Patients of at least 16 years (no upper age limit) with active UC defined as: CRP \\> = 5 mg\u002FL OR FCP \\> = 250 μg\u002Fg OR Mayo endoscopy subscore \\> = 2. Are switching to a new mechanism of action (MOA) onto either anti-TNFα therapy or vedolizumab\n\nOR\n\n2c. Non-IBD participants who are attending for a lower GI colonoscopy at any participating site. On any hospital\u002F medical\u002F clinical screening list or any other appropriate list with no pathology found on examination.\n\nExclusion Criteria:\n\n1. Inability to give informed consent\n2. Any positive result from previous screening for serum hepatitis B surface antigen, hepatitis C or human immunodeficiency virus (HIV)\n3. An ongoing infection requiring treatment\n4. Clinical evidence of active COVID infection and\u002For evidence of active COVID determined by local standard care procedures\n5. Participation in a clinical study with pharmacological intervention within 3 months prior to Baseline visit.\n6. Current diagnosis of cancer\n7. Having received a solid organ or stem cell transplant\n8. Having received a transfusion of blood, plasma, or platelets within 120 days prior to enrolment\n9. Confirmed pregnancy at time of enrolment\n10. For non-IBD participants: A prior history of IBD (CD, UC, microscopic colitis, indeterminate colitis or IBD unspecified)\n11. Clinical judgement by the investigator that the patient should not participate in the study\n12. Under 16yrs of age",{"count":333,"type":23},240,"The goal of this observational study is to learn about the comparisons of inflammatory markers between IBD and non-IBD (control) participants.\n\nThe main question it aims to answer is:\n\nAre there differences in inflammatory markers between IBD and non-IBD (control) participants.",[336,337,315,338],"Gastro-Intestinal Disorder","Crohn Disease","Inflammatory Bowel Diseases",{"date":319,"type":38},{"date":341,"type":38},"2022-12-12",{"date":343,"type":23},"2027-12-31",{"name":44,"class":45},{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":354,"conditions":355,"keywords":357,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":368,"locationsCount":46},"100639096","accessing-the-clarity-and-acceptability-of-recruitment-materials-for-a-study-on-thoracic-aortic-disease-surveillance-100639096","NCT07574151","Accessing the Clarity and Acceptability of Recruitment Materials for a Study on Thoracic Aortic Disease Surveillance","Accessing the Clarity and Acceptability of Recruitment Materials for a Study on Thoracic Aortic Disease Surveillance: A Qualitative Feasibility Study.","ACCESS-TAD","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Able to read and understand English\n\nExclusion Criteria:\n\n* Individuals under 18\n* Individuals unable to provide informed consent\n* Individuals unable to read or understand English",{"count":58,"type":23},"People who are invited to take part in health research are usually given written information, such as invitation letters, and information sheets. These documents are essential because they help people understand what the study involves and decide whether they want to take part. However, many studies have shown that research information is often too complex, too long, or written in technical language. This can make it difficult for people to fully understand the study and give informed consent.\n\nThis study aims to assess how clear, accessible, and acceptable draft research documents are for a proposed future doctoral study related to thoracic aortic disease. Thoracic aortic disease is a long-term condition that requires regular monitoring, and people in surveillance programmes may be invited to take part in research. It is therefore important that study information is clear, sensitive, and easy to understand.\n\nIn this study, staff and students from the University's School of Health Sciences will be asked to review draft recruitment materials. These materials include a study invitation, an information sheet, and interview guide. Participants will be asked to give feedback on how easy the documents are to read, whether the information is clear, whether the tone feels appropriate, and whether the amount of information feels reasonable.\n\nThe study will also use a standard readability tool to assess whether the documents are written at a level suitable for the public.\n\nThis research does not involve patients and is considered low risk. Its purpose is to improve research materials before they are used with patients, helping to support informed consent, reduce confusion, and improve ethical and inclusive research practice in future studies.",[356],"Thoracic Aortic Disease",[358,359,360,361],"Surveillance","Recruitment materials","Clarity","Acceptability","2026-06-26",{"date":364,"type":38},"2026-06-30",{"date":366,"type":38},"2026-03-11",{"date":91,"type":23},{"name":44,"class":45},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":378,"conditions":379,"keywords":386,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":396,"leadSponsor":398,"locationsCount":46},"100644544","lifestyle-advice-in-cvd-100644544","NCT07672054","Lifestyle Advice in CVD","Perspectives and Experience of Patients From Minority Ethic Communities on Advice Provided About Diet and Lifestyle Advice in Management of Their Cardiovascular Disease","Inclusion Criteria:\n\n* Patients over the age of 18 years with a personal history of minority ethnicity (non-white) and a diagnosis of cardiovascular disease\n\nExclusion Criteria:\n\n* Patients with a personal history of white ethnicity Patients without a history of cardiovascular disease",{"count":377,"type":23},15,"Individuals living in the UK who are from ethnic minority communities have a higher risk of heart disease and strokes than white individuals. This risk arises from the social determinants of health. These include lifestyle factors such as diet, physical activity and smoking. Improving these lifestyle factors in individuals is an essential part of reducing the chances of heart attacks and stroke. Patients may have diets and lifestyles arising from their cultural and religious backgrounds but receive advice which is not aligned to their own customs and experiences. Receiving advice which is not relevant to their own types of diet and lifestyle customs may create difficulties for patients in managing their heart and circulation health. Moreover, the dissonance between advice given and patient-specific relevance may lead to poorer adherence to the recommendations made to manage their condition. This can lead to poorer health outcomes for these patients. In addition, they may be advised to adopt diets and behaviours which are not appropriate to their cultures and may be also difficult to put into practice. This is important because lifestyle advice aligned to a patient's existing diet, behaviours and cultural beliefs leads to improved control of these health conditions. Learning to provide dietary and lifestyle advice relevant to individual patients needs is an important skill for the clinicians caring for them.",[380,381,382,383,384,385],"Cardio Vascular Disease","Dietary Change","Dietary Behaviors","Diet Habits","Experience","Ethnicity",[184,387,385,388,389,390,391,392],"Cardiovascular disease","Behavioural change","Modification","Healthcare experience","Healthcare access","Medical education","2026-06-22",{"date":362,"type":38},{"date":317,"type":23},{"date":397,"type":23},"2027-01-31",{"name":44,"class":45},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":55,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":408,"conditions":409,"keywords":412,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":4},"100644174","surveillance-of-neonatal-endotracheal-tube-colonisation-100644174","NCT07664449","Surveillance of Neonatal Endotracheal Tube Colonisation","Surveillance Study of Endotracheal Tube Microbial Colonisation in Neonatal Intensive Care Units","NETT","Inclusion Criteria:\n\n* Infant of any gestational age (22 weeks gestation and upwards) who is expected to be intubated for more than 12 hours\n* All infants must have verbal or written informed consent from the parent\u002Fcarer\n* All infants must have a realistic prospect of survival as determined by the attending clinical team\n\nExclusion Criteria:\n\n* Infants that are not for active resuscitation\n* Infants that are undergoing end-of-life care\n* In situations where consent is not possible or provided",{"count":305,"type":23},"Babies in neonatal intensive care units (NICUs) sometimes need help breathing using a breathing tube (endotracheal tube, or ETT) connected to a breathing machine (ventilator). Over time, bacteria and other substances can build up on the inside of these tubes. This build-up may contribute to infections, inflammation, or breathing problems, but we do not fully understand how often this occurs or what is present within the tubes used in UK NICUs.\n\nThis surveillance study will collect breathing tubes that have been removed from babies who have been ventilated for more than 12 hours as part of their normal clinical care. No additional procedures or interventions will be performed on babies, and the tubes would otherwise be discarded.\n\nResearchers will examine the used tubes and any respiratory secretions (mucus) associated with them. Laboratory testing will identify any bacteria or other microorganisms present and analyse the chemical composition that has accumulated within the tubes and respiratory secretions. By studying these samples, we hope to better understand how breathing tubes become colonised over time and how this may relate to infection and lung health in newborn babies.\n\nThis study aims to identify the microorganisms that colonises ETT and map them in a contemporary UK neonatal cohort.\n\nThe information gained from this study may help improve infection surveillance, guide future research, and support the development of strategies to reduce complications associated with mechanical ventilation in vulnerable newborn infants.",[410,411],"Ventilation, Mechanical","Ventilation-Associated Pneumonia",[413,414,415,416],"ventilation","endotracheal tube colonisation","neonatal","biofilm colonisation","2026-06-17",{"date":419,"type":38},"2026-06-24",{"date":421,"type":23},"2026-07",{"date":423,"type":23},"2028-03",{"name":44,"class":45},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":432,"enrollmentInfo":433,"targetDuration":4,"studyType":24,"phases":434,"briefSummary":435,"conditions":436,"keywords":440,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":452,"locationsCount":46},"100641764","glycaemic-response-of-arabic-bread-100641764","NCT07652320","Glycaemic Response of Arabic Bread","Glycaemic Response to Arabic Bread Formulated With Alternative Flour Blends: A Comparison With Arabic Wheat Bread","Inclusion Criteria:\n\n* Participants will be adults living with overweight or obesity (Body Mass Index \\[BMI\\] \\> 25 kg\u002Fm²).\n* Participants will be of any gender.\n* Participants will be aged 18 to 65.\n* Participants will be from any sociodemographic background.\n* Participants will be able to provide informed consent.\n* Participants will be able to understand spoken and written English and be able to record their responses to questionnaires.\n\nExclusion Criteria:\n\n* Those with food allergies or intolerances to any of the study ingredients, including wheat, chickpeas, lentils, or peas, will not be eligible.\n* Individuals with a known diagnosis of metabolic or chronic health conditions, such as diabetes, insulin resistance, hypertension, or phenylketonuria, will be excluded due to the potential impact on glycaemic control and study outcomes.\n* Participants with a fasting blood glucose level of above 7.0 mmol\u002FL.\n* Use of medications that influence blood glucose levels (e.g., corticosteroids, antipsychotics, antiviral protease inhibitors) or substances that interfere with digestion and absorption (such as laxatives or fibre supplements) will result in exclusion.\n* Pregnant or breastfeeding individuals will not be included due to the physiological changes that may influence study outcomes.\n* Participants with implanted medical devices, including pacemakers, artificial organs, defibrillators, or joint replacements, will be excluded for safety considerations.\n* Anyone who has undergone major surgery or hospitalisation within the last 5 months will be deemed ineligible.\n* Individuals who have participated in another research study involving invasive procedures within the last 3 months will be excluded.","65 Years",{"count":84,"type":23},[26],"Bread remains one of the most widely consumed staple foods worldwide, with wheat flour serving as its traditional foundation. However, the widespread dependence on refined wheat-based bread has paralleled the rising prevalence of type 2 diabetes (T2D), partly owing to its high glycaemic index (GI), which results in rapid increases in blood glucose levels. Enhancing the nutritional quality of bread, therefore, represents an important target for dietary intervention.\n\nDeveloping alternative flour blends for bread production presents a potential strategy for improving glycaemic control and supporting glucose homeostasis. Accordingly, this clinical trial aims to determine whether the partial replacement of wheat flour with legume flours, including chickpea, pea, and lentil, in Arabic bread formulations can lower glycaemic responses compared with traditional Arabic wheat bread.",[437,438,439],"Overweight","Obesity","Glycaemic Response",[439,441,442,443,444,437,438,445,446,447],"Arabic Bread","Legume Flour","Wheat Flour","Postprandial Glucose","Satiety","Appetite","Crossover Study",{"date":393,"type":38},{"date":450,"type":23},"2026-06",{"date":192,"type":23},{"name":44,"class":45},{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":24,"phases":462,"briefSummary":463,"conditions":464,"keywords":469,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":46},"100590209","postoperative-electrical-muscle-stimulation-two-100590209","NCT06964438","Postoperative Electrical Muscle Stimulation Two","A Three-Arm Randomised Controlled Trial to Establish Effectiveness of NMES With or Without Protein Supplementation to Preserve Muscle Mass and Strength and Improve Functional Outcomes After Abdominal Surgery for GI Cancer","POEMS2","Inclusion Criteria:\n\n* Adult patients (age 18 or over at the time of diagnosis made at MDT (multi-disciplinary team meeting)\n* MDT outcome of colorectal or gastric cancer or non-invasive neoplasia (tissue-proven, or radiologically diagnosed and clinically suspected) with the intention to treat with curative abdominal surgery\n* Agreed management plan for open or minimally invasive (laparoscopic or robot assisted) segmental abdominal (colonic or gastric) resection at the Royal Derby Hospital\n* Sufficient mobility and fitness to complete normal ERAS (enhanced recovery after surgery) protocols following surgery\n* Basic conversational spoken English language\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Upper GI (gastrointestinal) cancer requiring thoracotomy\u002Fthoracoscopy\n* Pre-existing neuromuscular disease (including Parkinsons disease)\n* Pacemaker, implantable cardiac defibrillator or other implanted nerve stimulator device\n* Metal prostheses or other metal-work in either upper legs (hip\u002Fknee\u002Ffemur)\n* Dementia or other cognitive problem or language barrier causing an inability to follow instructions and operate NMES machine\n* Inability to give informed consent\n* Disability preventing completion of ERAS after surgery (requiring Zimmer frame\u002Fwheeled frame\u002Fwheelchair to mobilise or bed-bound)\n* Peripheral vascular disease\n* Epilepsy\n* Pre-existing diagnosis of chronic kidney disease or estimated glomerular filtration rate \\\u003C60 on screening visit\n* Pre-existing diagnosis of liver disease\n* Intubation or intensive care admission during study period (between day 0-5 post-op); (surgical high dependency unit patients will be included)\n* Return to theatre for surgical complication within first 5-days post operation\n* History of rhabdomyolysis\n* Pregnancy\n* Deep vein thrombosis within past 6-months\n* Allergy to whey protein\n* Patient refusal of whey protein products on grounds of dietary requirements or intolerance\n* Participating in another clinical trial concurrently or within the last 6 months\n* Known infection with blood borne virus",{"count":164,"type":23},[26],"Undesirable loss of skeletal muscle mass (atrophy) is a common feature of many diseases as well as ageing, bed rest and physical inactivity. Losing muscle can lead to a reduction in one's ability to perform physical activities, and reduce independence and overall health. Muscle mass loss occurs very quickly (i.e., within a few days) after surgery.\n\nThe investigators previous work has shown that neuromuscular electrical stimulation (NMES) of the thigh muscles on one side of the body can help maintain muscle mass and strength on the stimulated side after surgery. Since then, additional work has been carried out to find the most effective form of stimulation to build muscle.\n\nThe current study aims to use this refined stimulation protocol in a clinical trial on the wards after major abdominal surgery. The intervention will involve delivering stimulation to both thighs in the few days after surgery, so that the investigators can assess whether this stimulation can preserve muscle mass and strength, and also, patients' ability to perform physical activities after surgery. In addition, the study will aim to find out whether any benefit provided by electrical stimulation can be increased further by taking a protein supplement at the same time.",[465,466,467,468],"Surgery","Colorectal Cancer","Muscle Atrophy","Cancer Gi",[65,470,471,472,473,474,475,476,477,478,479],"neuromuscular electrical stimulation","NMES","rehabilitation","general surgery","colorectal surgery","laparotomy","laparoscopy","postoperative recovery","gastrointestinal cancer","gastrointestinal surgery","2026-06-10",{"date":482,"type":38},"2026-06-15",{"date":484,"type":38},"2025-06-05",{"date":486,"type":23},"2027-03-01",{"name":44,"class":45},{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":55,"sex":202,"minAge":19,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":498,"conditions":499,"keywords":501,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":4},"100640526","exploring-the-link-between-menopause-glucose-control-and-frozen-shoulder-in-women-100640526","NCT07603089","Exploring the Link Between Menopause, Glucose Control, and Frozen Shoulder in Women","Exploring the Association Between Menopausal Status, Metabolic Health, and Frozen Shoulder in Women: a Cross-sectional Observational Study","MENO-FROST","Part 1\n\nInclusion criteria:\n\n• Any women \\> 18 years with a history of frozen shoulder diagnosed by a clinician\n\nExclusion criteria:\n\n• Any women without a clear previous diagnosis of frozen shoulder\n\nPart 2:\n\nInclusion criteria:\n\n* Perimenopausal women (self-assessment)\n* Aged 40-60 years\n* Diagnosed with FS within the last 12 months OR\n* Matched controls (women aged 40-60 years without FS).\n\nExclusion criteria:\n\n* Diabetes mellitus,\n* Thyroid dysfunction,\n* Secondary FS (e.g. posttraumatic),\n* Use of medications influencing hormonal or metabolic parameters (e.g. hormone replacement therapy \\[HRT\\].",{"count":497,"type":23},340,"Background\n\nFrozen shoulder (FS) is a common condition and affects how the shoulder moves, making it very stiff and sore. The shoulder joint becomes inflamed and tightened due to scarring in the joint called fibrosis. It can take years to get better, and for around 50% of individuals the symptoms last even longer. FS causes a profound negative impact on physical and mental health, including disturbed sleep, low mood, difficulty performing everyday activities and, in many cases, are unable to continue working. FS affects around 1 in 10 people, and almost twice as many women as men between the ages of 40-60 years, but it is unknown why. It is thought to either be related to changes in sex hormones during the menopause, or due to the way the body handles sugar and fat, which changes with the menopause. However, associations between the menopause transition and FS are not well established and previous evidence has been poor quality. Current treatments include physiotherapy, a steroid injection or surgery but none of these treat the underlying cause of FS. Women with FS said they would like to know why they developed FS and more early treatment options to avoid a long recovery or an operation.\n\nAim This study aims to understand if there is a link between the menopause, changes in blood sugar levels and FS in women.\n\nPlan In Part 1, women who have had FS will fill in an electronic questionnaire to give us information about their menopause status at the onset of FS, how long their symptoms lasted, what treatments they tried, and if they had any other health conditions. This will enable us to determine the relationship between the menopause and the onset of FS.\n\nIn Part 2, the investigators will invite 18 perimenopausal women with recently diagnosed FS and 18 matched women without FS to attend a one-day visit at the University of Nottingham. The investigators will measure their blood sugar levels over two weeks using a small monitor on their arm. The investigators will assess their menopause symptoms and shoulder related outcomes using validated questionnaires. The investigators will assess their shoulder movement and measure body fat and muscle levels, physical activity levels, diet, and take a blood sample to test sex hormones, inflammation and lipids, as well as markers related to frozen shoulder. This will help us to assess the relationship between blood glucose control and the onset of FS in perimenopausal women.\n\nImpact This research will help us understand if there's a link between menopause, blood sugar control, and FS. It could lead to new clinical trials testing treatments early in FS, such as a glucose lowering medication or hormone therapy, to help women recover faster and avoid surgery. This may improve clinical outcomes in women with FS and reduce costs associated with treating FS. This important question came directly from patients and has not been studied in depth before. The investigators plan to share the results widely through health newsletters, podcasts, research conferences, and medical journals.",[500],"Frozen Shoulder",[502,503,504],"frozen shoulder","menopause","glucose","2026-05-17",{"date":507,"type":38},"2026-05-22",{"date":509,"type":23},"2026-08",{"date":511,"type":23},"2027-09",{"name":44,"class":45},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":521,"conditions":522,"keywords":525,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":46},"100637388","learning-differences-in-medical-education-100637388","NCT07585708","Learning Differences in Medical Education","What Are the Patient and Medical Student Perspectives on the Learning Needs and Expectations of Training of Future Doctors in Healthcare for Individuals With Learning Differences?","Inclusion Criteria:\n\n* Volunteers will be recruited from participants in teaching sessions to GEM medical students held in September and October 2025. This will be using convenience sampling. Up to 120 students currently on the GEM Year 1 preclinical programme at the time of the study will be invited to complete the study.\n\nExclusion Criteria:\n\n* All who do not meet the inclusion criteria defined above",{"count":377,"type":23},"A learning difference or disability is a reduction in intellectual ability (GMC, 2024). It causes lifelong difficulty with everyday activities. Different individuals require different levels of support. Individuals with learning disability may also have learning difficulties and mental health problems, but these conditions do not always co-exist. Learning difficulties affect the way someone processes information. They are not related to intelligence but can affect learning and education. People with learning differences can experience higher rates of mental and physical ill-health. The individual's life expectancy is shorter than the average for the population. This is related to access and experience of health care. These patients may experience discrimination affecting their healthcare.\n\nDiscrimination arises from staff and organisational attitudes towards patients and judgements about their quality of life. These individuals' care is also at risk of diagnostic overshadowing where a patient's symptoms are attributed to their disability rather than a disease. Many people with learning disabilities may find it harder to use healthcare services, and the investigators want to find out what challenges these individuals face. For example, do these patient have trouble understanding what is being said to them? Are there issues with getting an appointment or understanding the information about their health?\n\nThis project focuses on understanding the experiences of people with learning disabilities when they use health services. How easily do can these individuals communicate with their clinician? Are there barriers in accessing care? Do these individuals feel respected and listened to during their appointments? How should healthcare staff be trained to provide better care to these patients? The investigators will be speaking directly to patients with learning disabilities living in Derbyshire. This will be by interviews encouraging the patients to share their thoughts and experiences. The information the investigators gather will help understand these people's experiences of healthcare and how this could be improved. The investigators will also undertake an anonymised survey of medical students on their perceived learning needs regarding individuals with learning differences. This information will be used to develop educational resources for clinical teachers. medical students and staff. Working with the volunteers will better prepare future doctors to provide holistic care for patients with learning differences.",[523,384,524],"Healthcare Access","Learning Disabilities",[526,527,390,391,392],"Learning difference","Learning disability","2026-05-13",{"date":530,"type":38},"2026-05-18",{"date":532,"type":23},"2026-05-07",{"date":534,"type":23},"2026-12-31",{"name":44,"class":45},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":283,"maxAge":4,"enrollmentInfo":544,"targetDuration":546,"studyType":205,"phases":4,"briefSummary":547,"conditions":548,"keywords":550,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":46},"100638525","diathermy-on-diabetes-glucose-monitoring-effectiveness-100638525","NCT07583238","Diathermy On Diabetes Glucose Monitoring Effectiveness","Assessing the Impact of Intraoperative Diathermy on Accuracy and Functioning of Glucose Monitoring Systems","DODGE","Inclusion Criteria:\n\n* Diagnosis of type 1 diabetes mellitus.\n* Planned admission for elective surgery at Nottingham University Hospitals NHS Trust.\n* Currently routinely using a prescribed Abbott Libre-2, Abbott Libre-3, Dexcom G6 or Dexcom G7 glucose monitoring system to monitor glucose concentrations.\n* Aged 4 years or older on the day of surgery.\n* Ability to give informed consent \u002F ability of parent\u002Fcarer to give informed consent (as appropriate).\n\nExclusion Criteria:\n\n* Use of paracetamol above maximum dose within 7 days before the scheduled date of surgery (in adults with body weight under 51kg - maximum of 60mg\u002Fkg per day, in adults with body weight 51kg and above - maximum of 4g per day, in children - maximum dose as per their age as stated in the British National Formulary for Children)\n* Any use of hydroxyurea within 7 days before the scheduled date of surgery\n* Use of more than 500mg per day of ascorbic acid \u002F vitamin C within 7 days before the scheduled date of surgery\n* Currently taking medications as part of a clinical trial.",{"count":545,"type":23},126,"1 Day","The goal of this observational study is to investigate if diathermy (a surgical tool that uses electrical energy to control bleeding) has any affect on the accuracy and functioning of continuous glucose monitoring systems in adults and young people with Type 1 Diabetes. The main questions this study aims to answer is -\n\n\\- Does the accuracy of continuous glucose monitoring systems change after use of diathermy?\n\nParticipants will:\n\n* Have their height and weight checked.\n* Provide information about their medical history including type of diabetes, other medical conditions and any current medications they take.\n* Have paired glucose meter and sensor glucose measurements taken every 15-75 minutes from up to 4 hours before surgery until up to 4 hours after the end of surgery.\n* Have two blood samples taken to measure glucose levels, The first one will be before the use of diathermy and the second will be after the use of diathermy.",[549],"Type 1 Diabetes Mellitis",[551,552,553,554,555,556,557,558,559,560],"Continuous Glucose Monitoring Systems","Diathermy","Type 1 Diabetes Mellitus","Capillary blood glucose","Sensor blood glucose","Peri-operative care","Intra-operative T1DM management","pre-operative","post-operative","intraoperative","2026-05-06",{"date":528,"type":38},{"date":564,"type":23},"2026-05",{"date":566,"type":23},"2027-02",{"name":44,"class":45},{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":575,"maxAge":19,"enrollmentInfo":576,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":577,"conditions":578,"keywords":580,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":612,"locationsCount":46},"100607055","effective-dosing-of-burosumab-in-xlh-100607055","NCT07183579","Effective Dosing of Burosumab in XLH","A Retrospective Observational Study of the Effect of Dosing Regimen of Burosumab on Biochemical Control of Serum Phosphate Levels in Patients With X-linked Hypophosphataemia (XLH)","Inclusion Criteria:\n\n* A diagnosis of x-linked hypophosphataemia (XLH) including genetic confirmation of a PHEX mutation.\n* Has received at least 12 months of continuous Burosumab treatment under paediatric criteria (given Burosumab is not started till a child is 12 months old in England, the minimum age will, therefore, be 2 years old) prior to their 18th birthday.\n\nExclusion Criteria:\n\n* Burosumab received under adult criteria (patients who have received both Burosumab under paediatric arrangements and, subsequently, adult arrangements, can have data obtained during paediatric dosing included).","2 Years",{"count":204,"type":23},"X-linked hypophosphataemia (XLH) is a rare, hereditary condition. The genetic defect leads to low blood phosphate levels and vitamin D suppression. Phosphate is required for strong bones and teeth and to store energy in cells. Low phosphate leads to soft bones (rickets). Patients experience bowed legs, short stature, bone pain and dental pain.\n\nPrior to Burosumab, conventional treatment of XLH previously consisted of two medications. On this regimen, patients take oral phosphate supplements 4-6 times a day and an active form of vitamin D daily. This treatment can leave patients with residual symptoms. They report significant disabilities and reduced quality of life.\n\nBurosumab (Crysvita, Kyowa Kirin) is now the standard paediatric treatment for XLH. It is given once a fortnight by injection under the skin. Early studies used a starting dose of 0.4mg\u002Fkg per dose. NICE recommends a starting dose of 0.4mg\u002Fkg, a normal maintenance dose of 0.8mg\u002Fkg and a maximum of 2mg\u002Fkg (up to 90mg). The British National Formulary for Children (BNFC) gives the same advice.\n\nHowever, the European Medicines Agency recommends a starting dose of 0.8mg\u002Fkg per dose which is, therefore, the standard starting dose now. Some patients achieve symptom and biochemical control on less than 0.8 mg\u002Fkg per dose. They may be exposed to higher doses than necessary.\n\nTo date, approximately 200 patients have started on Burosumab in England. They are all managed by specialist centres. The rare status of XLH means there are relatively few patients in each centre. Treatment effects and trends can only be described by collating data from multiple centres.\n\nThe investigators will undertake a review across multiple English centres of the doses of Burosumab. The review will only collect data already in the patients' health records. It will look at factors affecting the starting dose. The investigators will assess the association between dose, blood markers and growth.",[579],"X-linked Hypophosphatemia (XLH)",[581,582,583,584,585,586,587,588,589,590,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605],"Hypophosphatemia, X-Linked Dominant","Rickets","Burosumab","Monoclonal Antibodies","Alkaline Phosphatase","Parathyroid Hormone","Retrospective Studies","Observational Study","Multicenter Study","Dose-Response Relationship, Drug","Child","Adolescent","Pediatrics","X-Linked Hypophosphatemia (XLH)","Metabolic Bone Disease","Crysvita","FGF23 Antibody","Real-World Evidence","Pragmatic Clinical Study","Serum Phosphate","Nephrocalcinosis","Paediatric Endocrinology","Treatment Outcome","Adverse Events","Drug Administration Schedule","2026-05-05",{"date":608,"type":38},"2026-05-11",{"date":610,"type":38},"2025-11-03",{"date":321,"type":23},{"name":44,"class":45},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":617,"acronym":618,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":620,"enrollmentInfo":621,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":623,"conditions":624,"keywords":626,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":46},"100636738","improving-patient-assessment-after-acute-kidney-injury-aki-100636738","NCT07569588","Improving Patient Assessment After Acute Kidney Injury (AKI)","IMPACT-AKI","Inclusion Criteria:\n\nObservational study workstream\n\n* Age 18-85 years\n* AKI stage 2 or 3 during hospital admission OR AKI stage 1 of at least 7 days duration during hospital admission\n* 60-90 days after peak creatinine Qualitative interview workstream\n* Age 18-85 years\n* AKI during hospital admission\n* 60-90 days after peak creatinine Participatory workshop workstream\n* Age 18-85 years\n* Relevant experience (as assessed by the investigator) which could include personal experience of an episode of hospitalised AKI as a patient of carer, experience of managing AKI or related problems in a professional capacity or knowledge of a particular community.\n\nExclusion Criteria:\n\nObservational study workstream\n\n* Inability to give informed consent\n* No baseline creatinine available in previous 12 months\n* Pregnancy or breastfeeding\n* Current treatment with dialysis\n* Renal transplant\n* Pacemaker in situ\n* Previous amputation\n* Allergy to Omnipaque contrast agent (WP1 only)\n* Manifest thyrotoxicosis (WP1 only)\n* Ascites or significant (grade 3 to 4) peripheral oedema, defined as ≥6 mm pit, lasting for \\>1 minute after 5-second compression over tibia or medial malleolus (WP1 only) Qualitative interview workstream\n* Inability to give informed consent\n* No baseline creatinine available in previous 12 months\n* Current treatment with dialysis\n* Renal transplant\n* Receiving palliative care Participatory workshop workstream\n* Inability to give informed consent\n* Inability to communicate in English (the qualitative workshops will be held in English)","85 Years",{"count":622,"type":23},100,"The goal of this clinical trial is to improve patient care after acute kidney injury (AKI). It has three related parts. The main questions it aims to answer are:\n\n1. Is creatinine or cystatin a more reliable assessment of kidney function after AKI?\n2. What are the experiences of patients after AKI?\n3. What interventions should be recommended to improve assessment and support of patients after AKI?\n\nParticipants will be asked to do one or more of:\n\n* blood tests to measure kidney function in different ways\n* have measurement of their body composition\n* complete questionnaires about their symptoms\n* have an interview with a researcher about their experiences\n* discussion to develop an action plan based on findings",[625],"Acute Kidney Injury",[627,628,629],"acute kidney injury","chronic kidney disease","patient reported outcome measures","2026-05-01",{"date":561,"type":38},{"date":633,"type":38},"2026-02-16",{"date":635,"type":23},"2029-10",{"name":44,"class":45},{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":643,"eligibilityCriteria":644,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":645,"enrollmentInfo":646,"targetDuration":4,"studyType":24,"phases":648,"briefSummary":649,"conditions":650,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":657,"leadSponsor":659,"locationsCount":46},"100636457","effects-of-hiit-following-ptr-programme-100636457","NCT07565935","Effects of HIIT Following PTR Programme","Can High-Intensity Interval Training (HIIT) Reduce the Risk of Diabetes Relapse Following Discharge From the NHS Path to Remission Programme? - a Pilot Study","HIITpostLCD","Inclusion Criteria:\n\n* Adults between the age of 18-70 years\n* Ability to provide informed consent\n* Completed the NHS Path to Remission programme and achieved diabetes remission (HbA1c \\\u003C48mmol\u002Fmol (6.5%), and off diabetes medications for at least three months)\n\nExclusion Criteria:\n\n* BMI \\> 40kg\u002Fm2\n* Current participation in a formal exercise regime\n* Current pregnancy or breastfeeding\n* Uncontrolled hypertension (blood pressure \\>160\u002F100mmHg)\n* History of cardiovascular disease:\n\n  * Symptomatic angina\n  * Heart failure (class III\u002FIV)\n  * Significant arrhythmias\n  * Right to left cardiac shunt\n  * Recent acute coronary syndrome\n  * Severe aortic valvular disease\n  * Active cardiac infection\n* Background of the following respiratory diseases:\n\n  * Pulmonary hypertension\n  * Significant COPD\n  * Uncontrolled asthma\n* History of malignancy undergoing current treatment or palliation\n* Presence of significant musculoskeletal, neurological or cerebrovascular disease\n* Any other medical condition deemed by the investigators to preclude inclusion into the study","70 Years",{"count":647,"type":23},20,[26],"Caloric restriction programmes are highly effective and safe interventions for inducing rapid weight loss and improvements in glycaemic control. The landmark DiRECT study showed that 68% of people completing a caloric restriction intervention achieved remission of type 2 diabetes (T2D) by one year. Consequently, the NHS Path to Remission (PTR) programme was developed to stimulate diabetes remission in individuals that meet certain criteria. Unfortunately, long-term follow-up of the DiRECT study suggests that in the majority of participants that achieved remission, diabetes relapses within 5 years. This necessitates a focus on identifying methods to improve long-term maintenance of diabetes remission.\n\nHigh-intensity interval training (HIIT) involves several brief bursts of intense exercise, interspersed with recovery breaks, and is becoming increasingly popular. HIIT can cause improvements in cardiovascular fitness, reduce blood pressure, and lower body fat content in only a fraction of the time of traditional exercise methods. Specific to T2D, HIIT has been shown to improve pancreatic beta cell function, which is critically important for maintenance of long-term diabetes remission.\n\nThis pilot study is being conducted to determine whether participating in a home-based HIIT training programme may help maintain beta cell function in individuals that have achieved diabetes remission following the NHS PTR programme. The study will take place at the Royal Derby Hospital.\n\nThe intention is to recruit 20 participants from Derbyshire or Nottinghamshire that have achieved diabetes remission in the NHS PTR programme. Participants will be recruited following discharge from the programme and allocated to either perform a HIIT training programme (intervention group), or continue with usual care (control group) for 16 weeks.\n\nBefore starting, participants will attend the research department to have initial measurements taken including bioimpedance, fasting bloods, an intravenous glucose tolerance test, muscle ultrasound, electromyography and cardiopulmonary exercise testing. Following this, those in the intervention group will be asked to perform a home-based HIIT training programme 3 times per week and record details of each session in a booklet. The control group will be asked to continue with their habitual levels of physical activity. Participants will be contacted regularly to ensure their safety and compliance.",[651,652],"Obesity & Overweight","Type 2 Diabetes","2026-04-29",{"date":655,"type":38},"2026-05-04",{"date":564,"type":23},{"date":658,"type":23},"2027-05",{"name":44,"class":45},{"id":661,"slug":662,"hasResults":12,"nctId":663,"briefTitle":664,"officialTitle":665,"acronym":666,"eligibilityCriteria":667,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":668,"enrollmentInfo":669,"targetDuration":4,"studyType":205,"phases":4,"briefSummary":671,"conditions":672,"keywords":674,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":681,"startDateStruct":682,"completionDateStruct":684,"leadSponsor":686,"locationsCount":46},"100602197","an-exploration-of-sleep-disturbance-and-outcomes-in-tbi-sleep-tbi-100602197","NCT07120373","An Exploration of Sleep Disturbance and Outcomes in TBI (SLEEP-TBI)","An Exploration of the Relationship Between Sleep Disturbance, Mental Health, and Functional Outcomes in Mild, Moderate and Severe Traumatic Brain Injury (TBI): A Mixed Methods Study","SLEEP-TBI","Part 1\n\nInclusion criteria:\n\n* Age 18-60 years\n* Patients presenting to the Emergency Department within 24 hours of head injury\n* Medically diagnosed TBI of any severity\n* Glasgow Coma Scale (GCS) score documented on admission\n* Able to provide informed consent to take part in the study\n* To be able to wear an activity tracker for a period of 2 weeks, in usual home environment within 12 weeks of injury\n\nExclusion criteria:\n\n* Unable to understand the study requirements or give informed consent\n* Other diagnosed neurological condition such as, but not limited to, stroke, brain tumour, epilepsy, motor neuron disease, Parkinson's disease, or spinal cord injury\n* No definition of TBI or description of TBI severity, patient report only, or unknown time since injury\n* Pre-existing sleep disorder (self-reported or from clinical records)\n* Individuals that have working patterns that include night shifts\n* Not contactable via telephone, letter or email\n\nPart 2\n\nInclusion criteria:\n\n* Age 18-60 years\n* Medically diagnosed TBI of any severity\n* Glasgow Coma Scale (GCS) score documented in medical notes\n* Able to provide informed consent to take part in the study\n* TBI sustained \\>12 months\n* Able to wear an activity tracker in usual home environment for a period of 2 weeks\n\nExclusion criteria:\n\n* Unable to understand the study requirements or give informed consent\n* Other diagnosed neurological condition such as, but not limited to, stroke, brain tumour, epilepsy, motor neuron disease, Parkinson's disease, or spinal cord injury\n* No definition of TBI or description of TBI severity, patient report only, or unknown time since injury\n* Pre-existing sleep disorder (self-reported or from clinical records)\n* Individuals that have working patterns that include night shifts\n* Not contactable via telephone, letter or email\n\nPart 2 - For clinicians\n\nInclusion criteria:\n\n* A registered healthcare professional working at Nottingham University Hospitals Trust\n* Clinical experience of delivering rehabilitation services to participants with TBI that have been recruited to the study\n\nExclusion criteria:\n\n* Not contactable via telephone, letter or email\n* Unable to understand the study requirements or give informed consent\n\nPart 3\n\n• Inclusion\u002FExclusion criteria as stated above. 50% of participants will be recruited from Part 1, and 50% of participants will be recruited from Part 2 for both studies.","60 Years",{"count":670,"type":23},180,"This study aims to look at how sleep disturbance affects people who have had a traumatic brain injury.\n\nSleep disturbance can include waking frequently in the night, difficulty falling asleep, excessive sleepiness or changes to usual sleep patterns.\n\nInvestigators define traumatic brain injury as an injury caused by a forceful bump, blow, or jolt to the head or body, or from an object entering the brain. This results in a disturbance of normal brain function, that can be temporary.\n\nBy understanding the relationship between sleep disturbance and traumatic brain injury, investigators will hopefully improve care and treatment for people with a traumatic brain injury.\n\nInvestigators are looking to understand each participant's experience of sleep disturbance, as well as measuring sleep, using a device that monitors movement and sleep quality.\n\nInvestigators are interested how sleep disturbance impacts things like day-to-day life and activities, such as work or leisure. Investigators are also interested in mental health, such as depression or anxiety.",[673],"Traumatic Brain Injury",[675,676,677,678,679,680],"Sleep disturbance","Head injury","Traumatic brain injury","Sleep","Actigraphy","TBI",{"date":561,"type":38},{"date":683,"type":38},"2025-10-21",{"date":685,"type":23},"2026-12",{"name":44,"class":45},{"id":688,"slug":689,"hasResults":12,"nctId":690,"briefTitle":691,"officialTitle":692,"acronym":693,"eligibilityCriteria":694,"healthyVolunteers":55,"sex":18,"minAge":19,"maxAge":432,"enrollmentInfo":695,"targetDuration":4,"studyType":24,"phases":697,"briefSummary":699,"conditions":700,"keywords":701,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":703,"lastUpdatePostDateStruct":704,"startDateStruct":705,"completionDateStruct":707,"leadSponsor":709,"locationsCount":46},"100636725","early-phase-1-proof-of-principle-study-for-an-efficacy-trial-of-linaclotide-for-cystic-fibrosis-100636725","NCT07569419","Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis","A Randomised, Placebo-controlled Crossover Study Defining the Mode of Action of Linaclotide in Healthy Volunteers Using MRI","MODEL","Inclusion Criteria:\n\nParticipant is willing and able to give informed consent for participation in the study\n\nNot currently taking any medications (except for selective serotonin reuptake inhibitors, low dose tricyclic antidepressants, antihistamines, and oral contraceptive pill).\n\nAged between 18-60 years.\n\nAbility to conform to the study protocol, including overnight fasting, dietary and lifestyle restriction, administering linaclotide and placebo intervention, MRI scanning, consuming the rice pudding\u002Fblue dye meal, and rating stool frequency and appearance.\n\nExclusion Criteria:\n\nContraindication to MRI scanning (i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury, unable to lie flat and relatively still for less than 5 minutes.)\n\nPregnancy, lactating, or planning pregnancy during the investigation declared by candidate.\n\nHistory declared by the candidate of pre-existing gastrointestinal disorder that may affect bowel function.\n\nReported history of previous resection of the oesophagus, stomach, or intestine (excluding appendix).\n\nIntestinal stoma.\n\nAny medical condition that may potentially compromise participation in the study e.g., known food intolerance to rice pudding, known contraindication to the oral administration of linaclotide or placebo.\n\nHas a body mass index (BMI) value less than 18.5 or greater than 35.\n\nWill not agree to follow dietary and lifestyle restrictions required.\n\nUnable to stop drugs known to alter GI motility including mebeverine, opiates, monoamine oxidase inhibitors, phenothiazines, benzodiazepines, calcium channel antagonists for the duration of the study.\n\nParticipants who are currently (or in the past 3 months) taking antibiotics or probiotics as these may impact GI function.\n\nParticipation in night shift work the week prior to the study day. Night work is defined as working between midnight and 6.00 AM.\n\nAnyone who in the opinion of the investigator is unlikely to be able to comply with the protocol e.g., cognitive dysfunction, chaotic lifestyle related to substance abuse.\n\nHaving taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance\n\n\\-",{"count":696,"type":23},26,[698],"EARLY_PHASE1","Linaclotide is a medicine used to treat constipation and irritable bowel syndrome with constipation (IBS-C). It works by acting on the surface of the gut lining, where it increases the movement of salt and water into the bowel. This softens stools, makes them easier to pass, and can also reduce gut pain\n\nOne advantage of linaclotide is that, unlike some natural substances in the gut, it is stable and can act throughout the intestine. Studies in animals show that it has the strongest effect in the upper small intestine, but it may act in other parts of the bowel as well. In people, however, it is not yet clear whether linaclotide mainly works in the small intestine or in the large intestine (colon). Knowing this is important, because it could help the investigators understand whether linaclotide might also be useful in other conditions, such as cystic fibrosis, where the gut does not handle fluid properly.\n\nLinaclotide is taken as a capsule, but less than 1% is absorbed into the bloodstream. Instead, it stays in the gut, where it is broken down into smaller active parts. This means both the small intestine and colon may be exposed to its effects.\n\nUntil now, it has been hard to study this because traditional methods only measure one part of the gut at a time. A team at the University of Nottingham has developed MRI scanning methods that can safely and non-invasively measure water content in the small intestine and colon.\n\nThe aim of this pilot study is to use MRI in healthy volunteers to see exactly where linaclotide acts. This knowledge will help optimise future studies in conditions such as cystic fibrosis.",[29],[33,32,702,31],"gastrointestinal","2026-04-28",{"date":561,"type":38},{"date":706,"type":38},"2026-03-09",{"date":708,"type":23},"2026-10",{"name":44,"class":45},""]